Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

著者: Mark C. Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert‐Roth, Ying Zhang, Yijie Zhou, Mohamed‐Eslam F. Mohamed, Sebastian Meerwein, Aileen L. Pangan - The Lancet 2018 被引用: 443